STAT+: Pharmalittle: FDA declines to approve higher dose version of Regeneron eye drug; FDA warns wholesaler over counterfeit HIV pills
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Category: Pharmalot
.jpg)
STAT+: FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines
A year after two major drugmakers sued a wholesaler for its alleged role in distributing…
STAT+: Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit
Eli Lilly agreed to pay $2.4 million as part of a settlement with the U.S….
STAT+: Pharmalittle: Lilly drug shows biggest weight loss yet in mid-stage trial; Biogen shareholders elect director’s romantic partner to the board
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Nearly half of U.S. adults would spend $100 a month for weight loss drugs; Pfizer scraps an obesity pill
Good morning, everyone. and welcome to another working week. We hope the weekend respite was…
STAT+: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs
Almost half of Americans would be willing to spend up to $100 a month for…
STAT+: Pharmalittle: FDA approves first gene therapy for Duchenne muscular dystrophy; states join FTC to stop Amgen deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: GSK settles first lawsuit set for a U.S. trial over cancer links to Zantac
GSK reached a settlement with a man who claimed its Zantac heartburn medication caused his…
STAT+: Pharmalittle: Europe regulator raised safety signal on Novo drugs; U.S. seeks new trial over royalties on Gilead HIV prevention pills
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: U.S. seeks a new trial over royalties on Gilead HIV prevention pills
The U.S. government asked a federal judge to overturn a recent case in which a…
STAT+: Pharmalittle: Novo Nordisk sues spas, clinics over compounded Wegovy; top lobbyist leaves PhRMA
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss
In the latest fracas over obesity drugs, Novo Nordisk filed lawsuits alleging several medical spas,…
STAT+: Pharmalittle: Opaque conflicts permeate prescription drug benefits; Sanofi prevails in Zantac arbitration
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharmalittle: Bristol Myers sues HHS over Medicare drug negotiations; Lilly reports new shortages of Mounjaro diabetes drug
Good morning, everyone, and welcome to another working week, albeit an abbreviated one for many,…
STAT+: Trade group scolds drugmaker for ‘unethical’ attempt to gain info about rival product
In a notable move, a U.K. trade group has rebuked Leo Pharma for a “serious…
STAT+: Pharmalittle: FDA cites another troubled plant at company contributing to cancer drug shortages; USDA to push food producers over antibiotic claims
And so, another working week will soon draw to a close. Not a moment too…
STAT+: USDA to push food producers to substantiate claims that animals are raised without antibiotics
The U.S. Department of Agriculture is launching a program to ensure food producers substantiate claims…
STAT+: Pharmalittle: PBMs are targeted in yet another congressional bill; access to new Alzheimer’s drug may not happen quickly
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Bitter infighting leads 15 chapters to break away from leading ALS advocacy group
After a bitter dispute, the ALS Association has settled a lawsuit filed by 15 chapters…
STAT+: Sanders wants NIH to adopt ‘reasonable pricing’ language for drugs that agency research helps develop
In another bid to lower prescription drug prices, U.S. Sen. Bernie Sanders (I-Vt.) issued a…
STAT+: Pharmalittle: Exec nominated to Biogen board is mother of outgoing director’s child; telehealth company pauses Wegovy ads amid shortages
Top of the morning to you, and a fine one it is. Sunny skies and…
STAT+: Pharmalittle: U.S. Chamber sues over Medicare price negotiations; FDA seeks new supplier for scarce cancer drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis
Two large drugmakers and two of the biggest pharmacy chains finalized a $17.3 billion deal…
STAT+: Pharmalittle: FDA panel to review Alzheimer’s treatment; FDA advisers back approval of RSV drug for children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits
Rise and shine, everyone, another busy day is on the way, although the smoky covering…
STAT+: Pharmalittle: U.K. launches pilot to expand access to weight loss drugs; European Union approves RSV vaccine
Top of the morning to you, and a fine one it is. Well, sort of….
STAT+: FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply
After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy…
STAT+: Pharmalittle: Merck sues U.S. to halt Medicare drug-price negotiation; FDA oncology head wants advisory panels to keep voting on new drugs
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel
The Food and Drug Administration has removed a neurologist with financial ties to Biogen and…
STAT+: Pharmalittle: AstraZeneca lung cancer drug halves death risk; 400 Grail patients incorrectly told they may have cancer
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: To push antibiotic makers to be more green, a new system will certify manufacturing practices
In response to concerns about pollution caused by antibiotic production, an industry group is launching…
STAT+: Pharmalittle: Medicare holds firm on Alzheimer’s drug coverage policy; Pfizer says antibiotic combo can treat some superbugs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on the back half…
STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira —…
STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment
Hey there. STAT reporter Andrew Joseph here welcoming you to Wednesday’s edition of Pharmalittle, with…
Sacklers win appeal that shields them from opioid lawsuits, clearing way for bankruptcy settlement
A federal appeals court ruled Tuesday Purdue Pharma can shield its owners — members of…
STAT+: Pharmalittle: Pfizer touts study data for hemophilia drug; former Novartis execs cleared of bribery in Greece
Good morning, everyone, and how are you today? We are doing find, thank you, especially…
STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
Amid concern that HIV prevention pills are not being widely taken by those at highest…
STAT+: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis
Oh, what a beautiful morning. Yes, this is a cliché, but the saying is apt,…
STAT+: Pharmalittle: Biden administration proposes yearly audit for costliest Medicaid drugs; few at high risk of HIV take prevention pills
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Pharmalittle: Pfizer and Novo disclose upbeat data on oral weight loss drugs; PBM trade group blasts House committee over hearing
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: Seagen criticized by shareholder advisory firm for ‘problematic’ executive compensation ahead of Pfizer acquisition
As Seagen prepares to be acquired by Pfizer, an investor advisory firm is raising concerns…
STAT+: Pharmalittle: Many employer health plans won’t pay for obesity drugs; FDA panel rejects Intercept NASH drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Study: 1 in 5 primary endpoints changed in late-stage trials of cancer drugs already underway
Amid increased concerns over a lack of transparency in clinical trials, a new study found…
STAT+: Pharmalittle: AstraZeneca plans to ‘love’ China’s Communist Party; U.S. Supreme Court rules against Amgen in patent case
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Supreme Court rules against Amgen in closely watched case over scope of patent claims
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld…
STAT+: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs
Top of the morning to you, and a fine one it is. Once again, crystal…
STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations
The Federal Trade Commission is widening its probe into pharmacy benefit managers and their impact…